Exchange: NASDAQ·Updated 07:57 PM EST

ACB News

News
all
press releases
The Big Winner From the Aurora Cannabis-Organigram Deal: Curaleaf
Key PointsOrganigram is acquiring Aurora Cannabis...
Nasdaq News: Markets
The Big Winner From the Aurora Cannabis-Organigram Deal: Curaleaf
Key PointsOrganigram is acquiring Aurora Cannabis...
Nasdaq News: Markets
More News
Aurora Cannabis (ACB) delivered earnings and revenue surprises of +200.00% and +17.21%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Aurora Cannabis Inc. (the Company or Aurora) (NASDAQ | TSX: ACB), a leading Canada-based global medical cannabis company, today announced its financial and operational results for the second quarter 2027 ending September 30, 2026. Aurora has cancelled its investor call, originally scheduled for...
Business Wire
Aurora Cannabis shares surged after Organigram agreed to a C$561 million buyout, but competing bids, deal conditions and shareholder uncertainty remain.
Zacks
Curaleaf Issues Statement Regarding Alternative Proposal for Aurora Cannabis Curaleaf Issues Statement Regarding Alternative Proposal for Aurora CannabisPR NewswireSTAMFORD, Conn., Nov. 3, 2026 STAMFORD, Conn., Nov. 3, 2026 /PRNewswire/ -- Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF...
PR Newswire
Organigram is set to acquire Aurora for C$7.80 per share, a 32.4% premium to the stock’s closing price on Monday.
Stocktwits
Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) (Organigram) and Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) (Aurora) today announced that they have entered into an arrangement agreement (the Arrangement Agreement) pursuant to which Organigram will acquire all of the issued and outstanding common...
Business Wire
Aurora Cannabis Inc. (the Company or Aurora) (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, announced today that it will host an investor conference call on Thursday, November 12, 2026 at 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time to discuss its...
Business Wire
SNDL's Q3 sales beat expectations, but margin pressure and persistent cannabis weakness cloud its recovery. Can buybacks and U.S. expansion turn the tide?
Zacks
Aurora Cannabis heads into Q2 earnings with revenues expected to fall 20.1%, as market exits and reimbursement cuts weigh on results while international medical cannabis markets offer support.
Zacks

Advertisement|Remove ads.